Overview

Anat Burkovitz is the Co-Founder and CEO of Trojan Bio, a pioneering immunotherapy company. Since its inception in 2021, she has led Trojan Bio from concept to securing funding and establishing Trojan’s technology for harnessing antiviral immunity to fight cancer. Prior to founding Trojan Bio, Anat led the Israeli team for the NIAID program on SARS-CoV-2 Assessment of Viral Evolution, a global mission funded by the NIH to understand SARS-CoV-2 evolution and its relation to human immunity. Anat also served as a project leader at the National Institute for Biotechnology in the Negev (NIBN), working on therapeutic protein de-immunization in collaboration with pharmaceutical companies. Anat holds a Ph.D. in Computational Biology from Bar-Ilan University, where she focused on the design and engineering of therapeutic antibodies for cancer treatment. Anat is an inventor on multiple patents related to immunogenic peptide delivery and antibodies with reduced immunogenicity, and she has co-authored numerous publications on computational immunology and antibody engineering.